Solix EAI Pharma
The Next Frontier of Pharma AI
The right intelligence for every scientific decision — how agentic AI, semantic knowledge, and intelligent LLM orchestration are reshaping drug discovery and drug repurposing. The future of pharma AI is not about better models. It is about better scientific decisions. As researchers face an overwhelming volume of compounds, assays, omics, patents, and clinical evidence, the […]
Built Once, Used Many Times
Why Reuse Beats Reinvention on a Real Platform A shared substrate doesn’t compound anything on its own. It compounds only when the workflows running on top of it get reused instead of rebuilt. Blog 1 made the case that platforms compound because they have real anatomy underneath them – schema, taxonomy, workflow expertise, ontology, intelligence […]
One Substrate, Eight Workflows
How a Single Semantic Layer Powers Solix EAI Pharma’s Discovery Stack If a platform’s anatomy is real, adding an eighth capability shouldn’t require rebuilding the first seven. Our last post argued, alongside Patrick Grady’s two-part “On Platforms” series, that AI compounds only when it sits on a real anatomy — schema, taxonomy, workflow expertise, ontology, […]
Tools Automate. Platforms Compound.
Why Architecture — and Anatomy — Beat a Pile of Point Solutions in Pharma AI Every pharma R&D organization now owns more AI tools than it did three years ago — and, by most internal accounts, less clarity about what any of them are learning together. That paradox is the subject of a two-part series […]
The $2.6 Billion Lesson: What Pharma’s Failed Programs Are Trying to Tell Us
Every terminated drug program leaves behind a fingerprint of why it failed. AI can now read those fingerprints — and turn them into the blueprint for the next success Pharmaceutical R&D generates failure at an extraordinary rate — and buries it. >90% of discovery programs never reach an IND. ~70% of Phase II trials fail […]
